Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIR-Incompatible SCT for High-Risk AML in Children
NCT00553202Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Jan 2008
- Primary completion
- Jun 2016
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of allogeneic hematopoietic stem cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Children's Oncology Group. Primary endpoints: Overall Survival at 5 years and Cumulative Incidence of NK Cell Reconstitution at 5 years. Started Jan 2008; status: completed.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00553202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553202.